Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.68 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 4/20 | 0.35 |
| ▸ | GABRD | O14764 | 4/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.35 |
| ▸ | GABRE | P78334 | 4/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196696 | 1.00 | SLC7A5 (0.68) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL197140 | 1.00 | SLC7A5 (0.68) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL4588481 | 1.00 | SLC7A5 (0.68) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL5966382 | 1.00 | SLC7A5 (0.68) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL18927234 | 0.92 | SLC7A5 (0.65) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL5065202 | 0.85 | — | — | |
| SCHEMBL13502414 | 0.82 | SLC7A5 (0.60) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL1813972 | 0.81 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL43678 | 0.81 | — | — | |
| Valine SCHEMBL8516 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008053172-A1 | ASSAY | QUEEN'S UNIVERSITY OF BELFAST (GB) | 2008-05-08 | — | — | WO | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| CN-116621931-A | Actinomycete cyclic lipopeptid compound and extraction method and application thereof | 上海交通大学医学院附属仁济医院 | 2023-08-22 | — | — | CN | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230106131-A1 | POLYPEPTIDE CONJUGATES FOR INTRACELLULAR DELIVERY OF STAPLED PEPTIDES | OHIO STATE INNOVATION FOUNDATION | 2023-04-06 | — | — | US | disclosed |
| CN-114980933-A | Compositions and methods for treating viral infections | 奇达拉治疗公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114390929-A | Compositions and methods for treating respiratory syncytial virus | 奇达拉治疗公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-113194983-A | Compositions and methods for treating viral infections | 奇达拉治疗公司 | 2021-07-30 | — | — | CN | disclosed |
| US-9783800-B2 | Method for producing peptides having azole-derived skeleton | THE UNIVERSITY OF TOKYO (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20170159046-A1 | Method for Producing Peptides Having Azole-Derived Skeleton | THE UNIVERSITY OF TOKYO (JP) | 2017-06-08 | — | — | US | disclosed |
| US-20020177725-A1 | Peptide inhibitors of hepatitis C virus NS3 protein | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2002-11-28 | — | — | US | disclosed |
| EP-1252178-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| US-5696230-A | ACYCLIC OLIGOPEPTIDE HAVING CONSTRAINED BACKBONE CONFORMATION AND SPASMOGENIC, PLATELET AGGREGATORY, NEUTROPHIL POLARIZATION AND/OR NEUTROPHIL ENZYME RELEASE ACTIVITY | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1997-12-09 | — | — | US | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | SLC7A5 860/4885SLC1A3 2604/4885SLC1A2 3427/4885 |
| US-20020177725-A1 | Peptide inhibitors of hepatitis C virus NS3 protein | VIP, PRSS1, SERPINB1 | SLC7A5 3026/4885SLC1A3 3680/4885SLC1A2 4572/4885 |
| US-20230106131-A1 | POLYPEPTIDE CONJUGATES FOR INTRACELLULAR DELIVERY OF STAPLED PEPTIDES | VIP, IAPP, TAP1 | SLC7A5 175/4885SLC1A3 597/4885SLC1A2 1345/4885 |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | SLC7A5 75/4885SLC1A3 172/4885SLC1A2 236/4885 |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | CES1, CYP51A1, SPINT2 | SLC7A5 2566/4885SLC1A3 3020/4885SLC1A2 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.